At a time when the largest mRNA Covid vaccine peer-reviewed study recently revealed increases in neurological, blood, and heart-related conditions, along with the pharma-industrial complex unleashing a 'blitzkrieg' of vaccine commercials across corporate media outlets, a new report has found that vaccines for respiratory syncytial virus could be causing a rare nervous system disorder in older adults. 

The New York Times has reported that new safety data for two RSV vaccines, presented at a meeting of scientific advisers to the Centers for Disease Control and Prevention on Thursday, indicates that Guillain-Barre syndrome - a rare condition where the immune system attacks nerve cells, leading to muscle weakness and paralysis - may have occurred in adults over 60 who received the vaccines. Two vaccines, Pfizer's Abrysvo and GSK's Arexvy, are currently available on the market.

Officials said the rare disease that attacks the immune system was found in two cases per 100,000 vaccinated, and added more data is needed to understand the risks. 

"At this point, due to the uncertainties and limitations, these early data cannot establish if there is an increased risk for GBS after vaccination in this age group," Dr. Thomas Shimabukuro, director of the CDC's Immunization Safety Office, said at the meeting on Thursday. 

Dr. Shimabukuro continued: Increased surveillance "will be better able to determine if an increased risk for GBS after RSV vaccination is present, and if so the magnitude of the risk."